Swiss Bioscience GmbH was established in 2014 in Switzerland and is specialized in producing pharmaceutical quality grade stems cells under cGMP* conditions. The cells are isolated from human adipose tissue to produce stromal vascular fraction (SVF) which is then purified and expanded to produce human adipose tissue derived stem cells (hADSCs).
Swiss Bioscience GmbH pursues research and development in the domain of stem cells, create new cell therapy based modalities for human medical use. Swiss Bioscience GmbH research program is based on utilisation of the paracrine effect of stem cells and is aimed at developing therapeutics from extracellular vesicles extracted from stem cells.
hADSC and SVF may only be used as a transplant product within the framework of a valid marketing authorization or within the framework of controlled clinical studies.
Company Details
- Employees
- 14
- Founded
- -
- Address
- Wagisstrasse, 27a,switzerland
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://swissbioscience.ch/
- HQ
- Schlieren, Zurich
Swiss Bioscience Gmbh Questions
Swiss Bioscience Gmbh's website is https://swissbioscience.ch/
Swiss Bioscience Gmbh's LinkedIn profile is https://ch.linkedin.com/company/swiss-bioscience
Swiss Bioscience Gmbh has
14 employees.
View email and phone details for 14
employees at Swiss Bioscience Gmbh.
Swiss Bioscience Gmbh's industry is
Pharmaceutical Manufacturing
Swiss Bioscience Gmbh's top competitors are
Repertoire Immune Medicines,
Virometix Ag,
Pharmabiome Ag,
Ontrack Biomedical Ag,
Novago Therapeutics,
Phytax,
Molecular Partners,
Dinamiqs,
Neurimmune Ag,
Mabylon Ag.
Swiss Bioscience Gmbh's categories are Pharmaceutical Manufacturing
Swiss Bioscience Gmbh's founding year is 2014
